3Z Pharmaceuticals Publishes Breakthrough Study on Shared Metabolic Pathways in ADHD Therapeutics
REYKJAVIK, Iceland, Feb. 24, 2025 /PRNewswire/ -- 3Z Pharmaceuticals, a CNS-focused therapeutic development specialist, today announced the publication of a groundbreaking study in The Journal of Pharmacology and Experimental Therapeutics, unveiling...
3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Groundbreaking ADHD Therapy
REYKJAVIK, Iceland, Feb. 17, 2025 /PRNewswire/ -- 3Z Pharmaceuticals today announced the publication of a transformative study in Neuropsychopharmacology, highlighting compelling scientific evidence that positions the mechanisms engaged by...